TWO SOLID HITS AND A WHIFF

Like most investors, I've spent the last several months vacillating between euphoria and despair. A self proclaimed smart investor descends into stupidity. Over and over again.

Of late, I've been encouraged by the performance of a couple of my holdings. Proof that a value investment approach can work over time. Markets will dive and confidence will sag, but some stocks will go up. I'm not discounting luck as a reason.

My last two posts, Smart Balance [SMBL] and Constellation Brands [STZ] are the holdings that have helped hold my net worth together during the market's flight away from commodities, Europe exposure, and other out of favor sectors. Since the first part of April, SMBL is up more than 70% and STZ has risen  over 45%. Both of these companies have good management and operating performance has been OK, but acquisitions have enlivened analysts and investors.

Mario Gabelli jumped on board Smart Balance and bought 5% of the company. He, and others, liked SMBL's acquisition of two gluten free product companies. The party at STZ didn't start when they owned Robert Modavi and a host of wine and spirit names plus 1/2 of Mexico's Modelo American distribution. But it sure started when they announced the purchase of the other half of Modelo's U.S. distribution. The financing is in place, but the final capital structure of the $1.5 billion deal isn't known. I'm sticking with SMBL longer term and may bail after awhile on STZ.

Now the whiff. I've written about Teva before stating that it is under valued and should produce good returns. When? It continues to act like a dead worm in the swimming pool out back; it just keeps sinking. I'm hopeful it has hit bottom and is resting at its low point. The same mindset that hated SMBL and STZ is at play with TEVA. It's hated for patent expirations, litigation, and who knows what else. Those concerns a overblown. Analysts are calling for $5.40 eps in 2012 and $5.80 in 2013. As a $39 stock the P/E is about 7X. Even as a "slow grower" it's worth more than 7X as the balance sheet is decent.

It's only a matter of time with TEVA and you get a 2% yield while waiting. Something will spark the investing community, maybe an acquisition like the other two companies or some break through drug or blockbuster generic opportunity, but it will happen and the upside is significant. I've been saying that for quite awhile, but I remain a believer.

When Is A Growth Stock Not A Growth Stock?

I need a diagnosis and this company's stock price needs a prescription. This growth company has become a value stock and it continues to lose value! Reports out of Tel Aviv this morning show TEVA dropping another 6 percent as the world worries about the U.S. debt downgrade. The way the company's share price has performed the past couple of years, it will probably crater on Monday also in American trading.

What's wrong with this picture? The numbers presented below usually would not accompany the chart depicted below. Revenue has grown from$11B in 2008 to $16B in 2010. They will be $18.5B this year and $20.6B in 2012. Gross profit has been growing steadily and net income has grown from 600MM in 2008 to $3.3B in 2010 or $4.54 eps. Analysts have that growing to $5.06 this year and $5.63 in 2012.

Teva isn't a one drug company. They have numerous business units and a nice compliment of generic and proprietary drugs. Yet it sells at a PEG of 93 and forward earnings of 7X. Obama is scary, but can he be that scary? I thought I was picking up a steal in the high $40s but I've been wrong ever since with this growth stock. I'll probably be more wrong Monday.